DAFTAR PUSTAKA

Baumann, M. H. *et al*., 2007. Pleural Tuberculosis in the United States: Incidence and Drug Resistance. *CHEST,* 131(4), pp. 1125-1132.

Bielsa, S. *et al*., 2012. Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions. *The International Journal of Tuberculosis and Lung Disease,* 17(1), pp. 85-89.

Carranza, C. & Chavez-Galan, L., 2019. Several Routes to the Same Destination: Inhibition of Phagosome-Lysosome Fusion by Mycobacterium tuberculosis. *The American Journal of the Medical Sciences,* 357(3), pp. 184-194.

Cepheid, 2020. *Xpert MTB/RIF Assay.* USA: Cepheid.

Choi, H. *et al*., 2016. Clinical and Laboratory Differences between Lymphocyte- and Neutrophil-Predominant Pleural Tuberculosis. *PLOS ONE,* 11(10).

Dahiya, B. *et al*., 2019. Detection of Mycobacterium tuberculosis lipoarabinomannan and CFP-10 (Rv3874) from urinary extracellular vesicles of tuberculosis patients by immuno-PCR. *Pathogens and Disease,* 77(5).

Deeks, J. J. & Altman, D. G., 2004. Diagnostic tests 4: likelihood ratios. *BMJ,* 329(7458), pp. 168-169.

Dheda, K. *et al*., 2009. Clinical Diagnostic Utility of IP-10 and LAM Antigen Levels for the Diagnosis of Tuberculous Pleural Effusions in a High Burden Setting. *PLoS ONE,* 4(3), pp. 1-7.

Du, J. *et al*., 2015. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. *Journal of Research in Medical Sciences,* 20(1), pp. 26-31.

Elbrolosy, A. M., Helbawy, R. H. E., Mansour, O. M. & Latif, R. A., 2021. Diagnostic utility of GeneXpert MTB/RIF assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis. *BMC Microbiology,* 21(144).

Flores, J., Cancino, J. C. & Chavez-Galan, L., 2021. Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It?. *Frontiers in Microbiology.*

Franco, J. L. M. *et al*., 2020. Host-Derived Lipids from Tuberculous Pleurisy Impair Macrophage Microbicidal-Associated Metabolic Activity. *Cell Press,* 33(13).

Gopalaswamy, R., Dusthackeer, V. N. A., Kannayan, S. & Subbian, S., 2021. Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance. *Journal of Respiration,* 1(2), pp. 141-164.

Heyderman, R. S. *et al*., 1998. Pleural tuberculosis in Harare, Zimbabwe: the relationship between human immunodeficiency virus, CD4 lymphocyte count, granuloma formation and disseminated disease. *Trop Med Intl Health,* 3(1), pp. 14-20.

Higgins, J. & Green, S., 2011. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.* s.l.:The Cochrane Collaboration.

Kemenkes, 2023. *Laporan Program Penanggulangan Tuberkulosis Tahun 2022.* Jakarta: KEMENTERIAN KESEHATAN REPUBLIK INDONESIA.

Kerkhoff, A. D. & Lawn, S. D., 2016. A breakthrough urine-based diagnostic test for HIV-associated tuberculosis. *Lancet,* 19(387), pp. 1139-1141.

Liang, Q. *et al*., 2019. An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay. *BMC Infectious Diseases,* 19(1), p. 548.

Lo Cascio, C. M. *et al*., 2021. Diagnosis of tuberculous pleural effusions: A review. *Respiratory Medicine,* Volume 188.

Macías, A. *et al*., 2019. Epidemiology and diagnosis of pleural tuberculosis in a low incidence country with high rate of immigrant population: A retrospective study. *International Journal of Infectious Diseases,* Volume 78, pp. 34-38.

McNally, E., Ross, C. & Gleeson, L. E., 2023. The tuberculous pleural effusion. *breathe,* 19(4).

Mitra, D. K. *et al*., 2005. Polarized helper T cells in tubercular pleural effusion: phenotypic identity and selective recruitment. *Journal of Immunology,* 35(8), pp. 2367-2375.

Mohapatra, A., Gaikwad, U., Ganga, R. T. & Sharma, P., 2024. Diagnostic accuracy of Lipoarabinomannan detection by lateral flow assay in pleural tuberculosis. *BMC Infectious Disease,* 24(4), p. 178.

Morimoto, T. *et al*., 2006. Level of antibodies against mycobacterial glycolipid in the effusion for diagnosis of tuberculous pleural effusion. *Respiratory Medicine,* 100(10), pp. 1775-1780.

Nahid, P. *et al*., 2012. Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy. *The Journal of Infectious Diseases,* 205(Suppl 2), pp. 159-168.

Nicol, M. P. *et al*., 2021. Accuracy of a Novel Urine Test, Fujifilm SILVAMP Tuberculosis Lipoarabinomannan, for the Diagnosis of Pulmonary Tuberculosis in Children. *Clinical Infectious Disease,* 72(9), pp. 280-288.

Nyaga, V. N. & Arbyn, M., 2022. *Archives of Public Health,* 80(95).

Organization, W. H., 2019. *Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV Policy Update.* Switzerland: WHO.

Page, M. J. *et al*., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ,* Volume 372.

Peng, L. *et al*., 2023. Developing a method to detect lipoarabinomannan in pleural fluid and assessing its diagnostic efficacy for tuberculous pleural effusion. *Heliyon,* Volume 9.

Pewsner, D. *et al*., 2004. Ruling a diagnosis in or out with “SpPIn” and “SnNOut”: a note of caution. *BMJ,* 329(7429), pp. 209-213.

Reddy, K. P. *et al*., 2021. Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. *Clinical Infectious Disease,* 73(7), pp. 2077-2085.

Rodrigues, T. S. *et al*., 2020. Interplay between alveolar epithelial and dendritic cells and Mycobacterium tuberculosis. *Journal of leukocyte biology,* 108(4), pp. 1139-1156.

Sahn, S. A. & Iseman, M. D., 1999. Tuberculous empyema. *Seminars in respiratory infections,* 14(1), pp. 82-87.

Sharma, S. K. *et al*., 2002. Cytokine Polarization in Miliary and Pleural Tuberculosis. *Journal of Cllinical Immunology,* Volume 22, pp. 345-352.

Shaw, J. A., Diacon, A. H. & Koegelenberg, C. F., 2019. Tuberculous pleural effusion. *Respirology,* 24(10), pp. 962-971.

Shbeer, A. M. & Robadi, I. A., 2024. liquid biopsy holds a promising approach for the early detection of cancer: Current information and future perspectives. *Pathology - Research and Practice,* Volume 254.

Shreffler, J. & Huecker, M. R., 2023. *Diagnostic Testing Accuracy: Sensitivity, Specificity, Predictive Values and Likelihood Ratios.* s.l.:StatPearls Publishing.

Vorster, M. J., Allwood, B. W., Diacon, A. H. & Koegelenberg, C. F., 2015. Tuberculous pleural effusions: advances and controversies. *Journal of Thoracic Disease,* 7(6), pp. 981-991.

Whiting, P. F. *et al*., 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of Internal Medicine,* 155(8), pp. 529-536.

Yokoyama, T. *et al*., 2005. Clinical utility of lipoarabinomannan antibody in pleural fluid for the diagnosis of tuberculous pleurisy. *Japanese Society of Chemotherapy and The Japanese Association for Infectious Disease,* Volume 11, pp. 81-83.

Yuan, C. *et al*., 2019. Mycobacterium tuberculosis Mannose-Capped Lipoarabinomannan Induces IL-10-Producing B Cells and Hinders CD4+Th1 Immunity. *iScience,* 25(11), pp. 13-30.

Zhang, M., Li, D. & Hu, Z.-D. H. Y.-L., 2020. The diagnostic utility of pleural markers for tuberculosis pleural effusion. *Annals of Translational Medicine,* 8(9).